MA35660B1 - Inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile - Google Patents

Inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile

Info

Publication number
MA35660B1
MA35660B1 MA37064A MA37064A MA35660B1 MA 35660 B1 MA35660 B1 MA 35660B1 MA 37064 A MA37064 A MA 37064A MA 37064 A MA37064 A MA 37064A MA 35660 B1 MA35660 B1 MA 35660B1
Authority
MA
Morocco
Prior art keywords
fragile
syndrome
treatment
inhibitors
pak protein
Prior art date
Application number
MA37064A
Other languages
English (en)
Inventor
John C Mckew
Wenwei Huang
David Campbell
Sergio G Duron
Mark Behnke
Min Shen
Original Assignee
Afraxis Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afraxis Holdings Inc filed Critical Afraxis Holdings Inc
Publication of MA35660B1 publication Critical patent/MA35660B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Cette invention concerne des inhibiteurs de la protéine pak et des méthodes d'utilisation d'inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile.
MA37064A 2011-11-04 2014-05-26 Inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile MA35660B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161555902P 2011-11-04 2011-11-04
PCT/US2012/063426 WO2013067434A1 (fr) 2011-11-04 2012-11-02 Inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile

Publications (1)

Publication Number Publication Date
MA35660B1 true MA35660B1 (fr) 2014-11-01

Family

ID=48192852

Family Applications (2)

Application Number Title Priority Date Filing Date
MA37064A MA35660B1 (fr) 2011-11-04 2014-05-26 Inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile
MA37065A MA35661B1 (fr) 2011-11-04 2014-05-26 Inhibiteurs de pak pour le traitement de troubles de prolifération cellulaire

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA37065A MA35661B1 (fr) 2011-11-04 2014-05-26 Inhibiteurs de pak pour le traitement de troubles de prolifération cellulaire

Country Status (20)

Country Link
US (2) US20130116263A1 (fr)
EP (2) EP2773643A4 (fr)
JP (2) JP2014532724A (fr)
KR (2) KR20140096098A (fr)
CN (2) CN104093717A (fr)
AR (1) AR089175A1 (fr)
AU (2) AU2012327187A1 (fr)
BR (2) BR112014010420A2 (fr)
CA (2) CA2854471A1 (fr)
CL (2) CL2014001131A1 (fr)
CO (1) CO7030960A2 (fr)
CR (2) CR20140250A (fr)
EA (2) EA201490925A1 (fr)
IL (2) IL232154A0 (fr)
MA (2) MA35660B1 (fr)
MX (2) MX2014005292A (fr)
PH (1) PH12014500995A1 (fr)
SG (2) SG11201401914WA (fr)
TW (1) TW201326169A (fr)
WO (2) WO2013067434A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011156780A2 (fr) * 2010-06-10 2011-12-15 Afraxis, Inc. 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones pour le traitement de troubles du snc
JP6170060B2 (ja) 2011-11-04 2017-07-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規アリール−キノリン誘導体
CN111793068A (zh) 2013-03-15 2020-10-20 西建卡尔有限责任公司 杂芳基化合物和其用途
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3943087A1 (fr) 2013-03-15 2022-01-26 Celgene CAR LLC Composés hétéroaryle et utilisations associées
WO2015011252A1 (fr) * 2013-07-26 2015-01-29 F. Hoffmann-La Roche Ag Inhibiteurs pyrimidine-pyridinone de sérine/thréonine kinase
WO2015120049A1 (fr) * 2014-02-07 2015-08-13 Principia Biopharma, Inc. Dérivés de quinolone utilisés en tant qu'inhibiteurs du récepteur du facteur de croissance des fibroblastes
JP6631616B2 (ja) 2014-07-26 2020-01-15 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用
EP3288556A4 (fr) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
US10694988B2 (en) * 2016-02-17 2020-06-30 Nuralogix Corporation System and method for detecting physiological state
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP7090037B2 (ja) * 2016-06-23 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー 新規な［１，２，３］トリアゾロ［４，５－ｄ］ピリミジン誘導体
WO2018013466A2 (fr) * 2016-07-15 2018-01-18 Dana-Farber Cancer Institute, Inc. Biomarqueurs prédictifs de la résistance endocrinienne dans le cancer du sein
CN106818805A (zh) * 2016-12-27 2017-06-13 东莞市联洲知识产权运营管理有限公司 一种天然乙酰胆碱酯酶抑制剂及其杀虫应用
CN107083428B (zh) * 2017-04-10 2020-09-25 徐州医科大学 Pak5在癌症诊断预后治疗及药物筛选中的应用
US20220002429A1 (en) * 2018-10-24 2022-01-06 Northwestern University Tumor cell aggregation inhibitors' for treating cancer
TWI748317B (zh) * 2019-01-03 2021-12-01 美商建南德克公司 吡啶并－嘧啶酮與喋啶酮化合物及使用方法
CN112213400B (zh) * 2019-07-09 2022-06-07 四川弘合生物科技有限公司 一种β-榄香烯及其有关物质的检测方法
CN110496128B (zh) * 2019-09-23 2022-09-30 吉林大学 利培酮或帕潘立酮在制备治疗弥漫性大b细胞淋巴瘤的药物中的应用
US11912668B2 (en) 2020-11-18 2024-02-27 Deciphera Pharmaceuticals, Llc GCN2 and perk kinase inhibitors and methods of use thereof
WO2022152259A1 (fr) * 2021-01-15 2022-07-21 江苏先声药业有限公司 Inhibiteur de cdk2/4/6, son procédé de préparation et son application
CN113046323A (zh) * 2021-04-02 2021-06-29 四川农业大学 一种基于miR-532-5p及其靶基因调控卵巢颗粒细胞的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201765A3 (fr) * 2000-10-16 2003-08-27 Axxima Pharmaceuticals Aktiengesellschaft Kinases cellulaires impliqués dans l'infection par cytomégalovirus et leur inhibition
EP2094698A1 (fr) * 2006-11-09 2009-09-02 F. Hoffmann-Roche AG Dérivés de 6-phényl-pyrido [2,3-d]pyrimidine-7-one substitués utilisés comme inhibiteurs de la kinase et méthodes d'utilisation de ceux-ci
EP2112150B1 (fr) * 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Inhibiteurs Raf améliorés
US8674095B2 (en) * 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions
US8372970B2 (en) * 2009-10-09 2013-02-12 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
WO2011156646A2 (fr) * 2010-06-09 2011-12-15 Afraxis, Inc. 8-(sulfonylaryl)pyrido[2,3-d]pyrimidin-7(8h)-ones pour le traitement de troubles du snc
WO2011156780A2 (fr) * 2010-06-10 2011-12-15 Afraxis, Inc. 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones pour le traitement de troubles du snc

Also Published As

Publication number Publication date
CA2854462A1 (fr) 2013-05-10
IL232154A0 (en) 2014-05-28
AU2012327187A1 (en) 2013-05-23
WO2013067423A1 (fr) 2013-05-10
IL232215A0 (en) 2014-06-30
MX2014005296A (es) 2014-08-27
AR089175A1 (es) 2014-08-06
CL2014001131A1 (es) 2014-08-22
CA2854471A1 (fr) 2013-05-10
JP2014532724A (ja) 2014-12-08
BR112014010420A2 (pt) 2017-04-25
CN104039786A (zh) 2014-09-10
CN104093717A (zh) 2014-10-08
CL2014001132A1 (es) 2014-08-22
EP2773643A4 (fr) 2015-07-29
AU2012327183A1 (en) 2013-05-30
SG11201401914WA (en) 2014-05-29
KR20140096098A (ko) 2014-08-04
CR20140251A (es) 2014-08-20
SG11201401996TA (en) 2014-05-29
EA201490925A1 (ru) 2014-09-30
KR20140105451A (ko) 2014-09-01
BR112014010631A2 (pt) 2017-04-25
EA201490927A1 (ru) 2014-10-30
CR20140250A (es) 2014-08-20
PH12014500995A1 (en) 2014-08-04
TW201326169A (zh) 2013-07-01
US20150031693A1 (en) 2015-01-29
AU2012327187A8 (en) 2013-07-25
CO7030960A2 (es) 2014-08-21
AU2012327183A8 (en) 2013-07-18
JP2015501786A (ja) 2015-01-19
US20130116263A1 (en) 2013-05-09
MX2014005292A (es) 2014-09-11
EP2773643A1 (fr) 2014-09-10
EP2773642A1 (fr) 2014-09-10
WO2013067434A1 (fr) 2013-05-10
MA35661B1 (fr) 2014-11-01

Similar Documents

Publication Publication Date Title
MA35660B1 (fr) Inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
EA201391329A1 (ru) Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3)
EA202193044A2 (ru) Способы лечения таупатии
EA201390274A1 (ru) Борсодержащие малые молекулы
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201170396A1 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
EA201490265A1 (ru) Ингибиторы тирозинкиназы брутона
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EP3725811A3 (fr) Compositions pour inhibition d'activation du complément dépendant de masp-2
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
EA201591786A1 (ru) Монотерапия gla для применения в лечении рака
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
UY34343A (es) Proteinas de unión al antígeno cd27l
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201300867A1 (ru) ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВ
EA201490688A1 (ru) 2-тиопиримидиноны
IN2014CN03555A (fr)
EA202091676A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
FR20C1044I2 (fr) Triazines pour le traitement des infections protozoïques
EA201792608A3 (ru) Применение белков p3 бактериофага в качестве агентов, связывающих амилоид
UA107346C2 (en) Use of nifuratel to treat infections caused by atopobium species